

Clinical Trial Protocol

Iranian Registry of Clinical Trials

26 May 2026

Evaluation of the effectiveness of co2 fractional laser with Platelet-Rich Plasma (PRP) and excimer lamp in comparison with co2 fractional laser with local tacrolimus and excimer lamp in patients with vitiligo

Protocol summary

Study aim

Determining the effectiveness of fractional co2 laser with Platelet-Rich Plasma (PRP) and excimer lamp in comparison with fractional co2 laser with local tacrolimus and excimer lamp in patients with vitiligo referred to Afzalipour Hospital in Kerman

Design

Clinical trial, with parallel, double-blind, randomized, single-phase groups on 36 patients. A table of numbers was used for randomization.

Settings and conduct

Patients in both groups receive three sessions of CO2 fractional laser at one-month intervals and an excimer lamp twice a week for a maximum of 12 weeks. In addition to laser injection, patients in group A use PRP injection and patients in group B use 0.1% tacrolimus ointment. Burning, itching, dryness, redness, flushing, scaling telangiectasia, secondary infection, and type of repigmentation are assessed by a physician who does not know the type of treatment.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients over 18 years of age with vitiligo who have not received any treatment for vitiligo for 3 months prior to enrollment Exclusion criteria: Uncontrolled systemic diseases, renal failure, history of allergy to calcineurin inhibitors and macrolides, Unstable vitiligo, age under 18, segmental vitiligo, involvement of more than 20% of the skin surface, history of autoimmune disease and use Other treatments, patient with Koebner-positive history, history of colloid and pregnancy and lactation

Intervention groups

For group A patients, in addition to excimer laser and CO2, PRP injection is performed monthly. Group B patients are treated with 0.1% tacrolimus ointment on the skin twice a day from the next day.

Main outcome variables

Burning, itching, dryness, redness, flushing, scaling telangiectasia, secondary infection and type of repigmentation

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210125050139N1**

Registration date: **2021-07-18, 1400/04/27**

Registration timing: **registered_while_recruiting**

Last update: **2021-07-18, 1400/04/27**

Update count: **0**

Registration date

2021-07-18, 1400/04/27

Registrant information

Name

Saleh Solhjou

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 77 3424 0219

Email address

saleh.s1991@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-06-05, 1400/03/15

Expected recruitment end date

2022-09-06, 1401/06/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effectiveness of co2 fractional laser with Platelet-Rich Plasma (PRP) and excimer lamp in comparison with co2 fractional laser with local tacrolimus and excimer lamp in patients with vitiligo

Public title

Efficacy of fractional co2 laser with PRP in patients with vitiligo

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Suffering from vitiligo Age over 18 years They have not received any treatment for vitiligo for 3 months before enrollment Among the patients referred to Afzalipour Hospital, Besat Clinic and Dermatology Center The diagnosis is made clinically by a dermatologist Confirmation of the disease by means of examination with a Wood lamp

Exclusion criteria:

Uncontrolled systemic diseases renal failure history of allergy to calcineurin inhibitors and macrolides age under 18 segmental vitiligo involvement of more than 20% of the skin surface history of autoimmune disease and use of other treatments patient With a positive Coubern history history of colloid and pregnancy and lactation

Age

From **18 years** old to **60 years** old

Gender

Both

Phase

1

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size

Target sample size: **18**

Randomization (investigator's opinion)

Randomized

Randomization description

simple randomization was done using minitab 16 software (Mini Tab Inc.)

Blinding (investigator's opinion)

Triple blinded

Blinding description

this is a triple-blind study for outcome assessor , patients and analyzer.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Kerman University of Medical Sciences

Street address

Ebne Sina Ave., Tahmasb Abad Blvd.

City

Kerman

Province

Kerman

Postal code

761614111

Approval date

2021-02-13, 1399/11/25

Ethics committee reference number

IR.KMU.AH.REC.1399.165

Health conditions studied**1****Description of health condition studied**

vitiligo

ICD-10 code

L80

ICD-10 code description

Vitiligo

Primary outcomes**1****Description**

Lesion area

Timepoint

at base line and 1, 2, 3, 4, 5 and 6 months later

Method of measurement

Measure the diameters of the depigmented lesion using a ruler

2**Description**

disease activity

Timepoint

at base line and 1, 2, 3, 4, 5 and 6 months later

Method of measurement

Measurement of disease activity based on VIDA SCORE

3**Description**

percentage of improvement

Timepoint

at base line and 1, 2, 3, 4, 5 and 6 months later

Method of measurement

By clinical examination of the lesion and measuring the percentage of lesion healing compared to the primary lesion

Secondary outcomes

1

Description

Erythema

Timepoint

at base line and 1, 2, 3, 4, 5 and 6 months later

Method of measurement

by physical examination and classification of the severity of adverse effects to mild , moderate and severe

2

Description

scaling

Timepoint

at base line and 1, 2, 3, 4, 5 and 6 months later

Method of measurement

by physical examination and classification of the severity of adverse effects to mild , moderate and severe

3

Description

pruritis

Timepoint

at base line and 1, 2, 3, 4, 5 and 6 months later

Method of measurement

by physical examination and classification of the severity of adverse effects to mild , moderate and severe

4

Description

secondary

Timepoint

at base line and 1, 2, 3, 4, 5 and 6 months later

Method of measurement

With clinical examination of the lesions and the presence of signs of infection such as purulent discharge and hotness

Intervention groups

1

Description

Intervention group: Co2 fractional laser (; Italy; Energy, 100mj; density, 100 / cm²; 2 passes DEKA) with, dwell time: 400, power: 6 w, dot mode spacing: 550. 3 sessions with one month intervals and lamp excimer (Medflash II, Italy; 308nm) twice a week for a maximum of 12 weeks starting at 0.5 J / cm². In this group, in addition after the PRP preparation, we inject 0.1 cc of the solution into the patient's blood at a distance of 1 cm.

Category

Treatment - Devices

2

Description

Control group: Co2 fractional laser (; Italy; Energy, 100mj; density, 100 / cm²; 2 passes DEKA) with, dwell time: 400, power: 6 w, dot mode spacing: 550 Three sessions with one month intervals and lamp excimer (Medflash II, Italy; 308nm) twice a week for a maximum of 12 weeks starting at 0.5 J / cm². In this group, in addition to this topical cream Tacrolimus 0.1% of Tehran Shimi Pharmaceutical Company is used twice a day for 3 months.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Afzalipour Hospital

Full name of responsible person

Maryam Khalili

Street address

Imam high way, Afzalipour Hospital

City

Kerman

Province

Kerman

Postal code

7616913911

Phone

+98 34 3132 8328

Email

maryam_khalili36@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kerman University of Medical Sciences

Full name of responsible person

Abbas Pardakhty

Street address

Ebne sina Aveue, Jahad Blvd

City

Kerman

Province

Kerman

Postal code

7619813159

Phone

+98 34 3226 3855

Email

abpardakhty@kmu.ac.ir

Grant name

Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Kerman University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Kerman University of Medical Sciences
Full name of responsible person
Maryam Khalili
Position
Assistant professor of dermatology
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Imam high way, Afzalipour Hospital
City
Kerman
Province
Kerman
Postal code
761691391
Phone
+98 34 3132 8328
Email
maryam_khalili36@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Kerman University of Medical Sciences
Full name of responsible person
Maryam Khalili
Position
Assistant professor of dermatology
Latest degree
Specialist
Other areas of specialty/work

Dermatology
Street address
Imam high way, Afzalipour Hospital
City
Kerman
Province
Kerman
Postal code
761691391
Phone
+98 34 3132 8328
Email
maryam_khalili36@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Kerman University of Medical Sciences
Full name of responsible person
Maryam Khalili
Position
Assistant professor of dermatology
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Imam high way, Afzalipour Hospital
City
Kerman
Province
Kerman
Postal code
761691391
Phone
+98 34 3132 8328
Email
maryam_khalili36@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available